Skip to main content
Clinical Trials/ACTRN12614000838617
ACTRN12614000838617
Completed
Phase 2

Investigating the Prevention of Endometrial CAncer with Metformin (PECAM Study)- a study involving postmenopausal women with hormone receptor positive breast cancer who are currently on tamoxifen therapy for at least 6 weeks.

Monash University0 sites130 target enrollmentAugust 7, 2014

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Endometrial cancer
Sponsor
Monash University
Enrollment
130
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 7, 2014
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Postmenopausal women, aged \< 75 years, who are currently taking tamoxifen therapy for at least 6 weeks for treatment of hormone receptor positive breast cancer.

Exclusion Criteria

  • 1\.Women who are premenopausal / perimenopausal / \> 75 years old
  • 2\.Women with advanced breast cancer and likely to have progression of their disease within the study period, as assessed by their treating oncologist.
  • 3\.Women with any of the following on screening:
  • a)Use of any systemic hormones in the last 6 months;
  • b) serious endocrine disorder with systemic disease;
  • c) alcohol consumption greater than 3 standard drinks per day;
  • d) known acute or chronic renal, liver disease or cardiovascular disease;
  • e) insulin dependent diabetes mellitus or use of an oral hypoglycemic agent;
  • 4\. \<6 months amenorrhoea so that the likelihood of ovulatory cycles during the study will be small.
  • 5\. EH with atypia or ECa on endometrial biopsy or hysteroscopy and curettage.

Outcomes

Primary Outcomes

Not specified

Similar Trials